Aging, Insulin Resistance Syndrome, Older Adults With Cognitive Decline
Conditions
Keywords
Glycine, Older Adults, Cognitive Decline, Brain-Derived Neutrophic Factor (BDNF), Inflammation
Brief summary
The purpose of this study was to evaluate the effects of daily glycine supplementation on metabolic health and cognitive performance in older adults. Over a period of six months, participants received 1,000 mg of glycine per day to determine if this amino acid could improve markers of insulin resistance, glucose metabolism, and cognitive functions such as memory and executive tasks. The research aimed to identify whether this nutritional intervention provides a safe and effective strategy to support healthy aging, focusing on the link between metabolic balance and brain health in the elderly population.
Detailed description
A 6-month longitudinal study was conducted, featuring a glycine supplementation phase followed by a dietary maintenance period. Cognitive assessments and serum BDNF levels were monitored at baseline, 3 months (T3), and 6 months (T6). Which included the evaluation of fasting glucose, insulin levels, insulin resistance indices, and specific metabolic biomarkers. Concurrently, cognitive functions were evaluated utilizing standardized neuropsychological instruments to measure changes in memory, attention, and executive function. Linear Mixed-Effects Models (LMM) were used to analyze temporal trajectories.
Interventions
DIETARY_SUPPLEMENTGlycine
Oral supplementation of glycine at a dose of 1,000 mg per day, administered daily over a 6-month period.
Sponsors
Brenda Sarahí Beristain Lujano
Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado
National Polytechnic Institute, Mexico
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Intervention model description
Single-group, open-label study designed to evaluate longitudinal changes in metabolic and cognitive parameters from baseline (T0) to 6 months (T6) following daily glycine supplementation.
Eligibility
Sex/Gender
ALL
Age
60 Years to 80 Years
Healthy volunteers
Yes
Inclusion criteria
-Individuals across all nutritional statuses according to Body Mass Index (BMI): underweight, normal weight, overweight, and obesity.
Exclusion criteria
* Clinically relevant comorbidities (requiring patient hospitalization or a diagnosis of any infectious/contagious disease). * Consumption of polyphenol-based supplements or herbal blends within the two weeks prior to the study. * Mental incapacity. * Lack of willingness. * Language barriers that prevent adequate understanding or co-operation.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Brain-Derived Neurotrophic Factor (BDNF) levels | Baseline (T0), 3 months (T3) and 6 months (T6) | Serum concentrations of Brain-Derived Neurotrophic Factor (BDNF) measured via ELISA. Unit of Measure: pg/mL |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Cognitive performance evaluated by the Cognitive performance was assessed using the Montreal Cognitive Assessment (MoCA). | Baseline (T0), 3 months (T3) and 6 months (T6) | Cognitive performance assessed using the Cognitive performance was assessed using the Montreal Cognitive Assessment (MoCA). Total scores range from 0 to 30, where higher scores indicate better cognitive performance. * ≥ 26 points: Considered within the normal range. * 18 - 25 points: Commonly associated with Mild Cognitive Impairment (MCI). * 10 - 17 points: Suggests Moderate Cognitive Impairment. * \< 10 points: Suggests Severe Cognitive Impairment. |
Countries
Mexico
Contacts
PRINCIPAL_INVESTIGATORBrenda Sarahí BS Beristain Lujano, MSc
Escuela Superior de Medicina IPN
Outcome results
None listed